Previous 10 | Next 10 |
2023-04-18 10:04:36 ET Gainers: Dermata Therapeutics ( DRMA ) +108% . BELLUS Health ( BLU ) +99% . Allarity Therapeutics ( ALLR ) +69% . Gamida Cell ( GMDA ) +37% . YS Biopharma ( YS ) +28% . Losers: China Jo-Jo Drugs...
2023-04-18 08:30:29 ET China Jo-Jo Drugstores ( CJJD ) -36% . Athersys ( ATHX ) -33% announces $3.7 million registered direct Offering and concurrent private placement. Presto Automation ( PRST ) -20% . Evaxion Biotech ( EVAX ) -20% promis...
2023-04-18 07:00:00 ET 3 Future Trends to Use for Your Penny Stocks Investing This Year The allure of penny stocks has captivated investors for years, and with good reason. These low-priced stocks offer the potential for exponential gains, often within a relatively short period. As the ...
2023-04-13 10:02:55 ET Gainers: Ocean Biomedical ( OCEA ) +24% . ContraFect ( CFRX ) +21% . bluebird bio ( BLUE ) +18% . Evaxion Biotech ( EVAX ) +17% . Hillstream BioPharma ( HILS ) +10% . Losers: GlucoTrack ( GCTK ) ...
2023-04-13 08:20:45 ET CXApp ( CXAI ) +56% . Ocean Biomedical ( OCEA ) +20% a nnounces notice of allowance for U.S. patent application for developing “whole new class” of Malaria therapeutics issued to scientific co-founder Dr. Jonathan Kurtis. ...
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism of Action of CF-370 YONKERS, N.Y., April 06, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical...
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatmen...
2023-03-31 08:43:34 ET Contrafect press release ( NASDAQ: CFRX ): Q4 GAAP EPS of -$16.14. The net loss in the current period includes $4.8 million, or $7.90 per share, of non-cash charges related to the value of the warrants issued in the Company’s December 2022 off...
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatmen...
Gainers: Cardio Diagnostics ( CDIO ) +159% . Bioventus ( BVS ) +68% . CNS Pharmaceuticals ( CNSP ) +24% . Bullfrog AI ( BFRG ) +20% . SI-BONE ( SIBN ) +19% . Losers: ContraFect ( CFRX ) -24% . AdaptHealth ( AHCO ) ...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023